ServiceNow Vulnerability Response for Life Sciences and Pharma

Vulnerability Response in life sciences is the process of finding, assessing and fixing security weaknesses in systems that must stay validated, such as manufacturing software and medical devices. The page explains how to choose between patching, revalidation, compensating controls and a recorded risk acceptance, and what evidence a quality reviewer will expect at each step.

Vulnerability Management in Regulated Life Sciences

Life sciences and pharmaceutical organizations operate critical systems for manufacturing, research, and patient care. Vulnerabilities in these systems can affect product quality, research integrity, and patient safety. Vulnerability Response in ServiceNow helps life sciences organizations identify vulnerabilities, assess risk in the context of regulatory requirements, and manage remediation while maintaining system validation and compliance.

Life sciences vulnerability management has unique constraints. A vulnerability in a validated manufacturing system cannot be patched immediately without revalidation. A vulnerability in a medical device might have limited remediation options because the device firmware is not easily updated. Vulnerability Response must account for these constraints and guide organizations through complex remediation decisions.

GMP and Validated System Patching

Validated systems in GMP environments cannot be patched casually. Each patch must be assessed for impact on system validation. A patch that modifies core functionality might invalidate the system, requiring revalidation before the system can be used in production. ServiceNow Vulnerability Response should include an impact assessment step: will this patch affect system validation? If yes, the remediation timeline might be weeks (time for revalidation) rather than days.

Many organizations maintain validated systems on older software versions that are no longer receiving patches. A system running an older, no-longer-supported version of database software has known vulnerabilities but patching would require revalidation. ServiceNow should track these situations, documenting the risk and the compensating controls in place. A database not connected to the internet, accessible only from internal networks, and monitored for intrusion, might have accepted risk.

Medical Device Cybersecurity

Medical devices (laboratory analyzers, infusion pumps, diagnostic equipment) increasingly have network connectivity and software. Vulnerabilities in medical device firmware can affect patient safety. Device manufacturers are responsible for security, but healthcare organizations must manage the devices in their environment and ensure patches are applied. ServiceNow Vulnerability Response should track medical device vulnerabilities and coordinate patching with the device vendor and biomedical team.

Some medical devices cannot be patched in the field; they must be returned to the manufacturer or upgraded on the manufacturer’s schedule. Organizations must decide: do we apply compensating controls (network isolation, access restrictions) until the device manufacturer releases a patch? Or do we discontinue use of the device? ServiceNow should help track these decisions and their justification.

Risk Assessment and Prioritization

Life sciences organizations should prioritize vulnerabilities based on risk: severity, exploitability, whether exploits are known in the wild, and whether the vulnerable system is internet-connected or exposed to threat. A critical vulnerability in a manufacturing system is higher risk than a critical vulnerability in a system not connected to the network. A vulnerability in a system handling patient data is higher risk than the same vulnerability in an internal administrative system.

ServiceNow Vulnerability Response should help organizations assess risk and prioritize remediation. A risk scoring model specific to the life sciences environment (considering GMP compliance, data sensitivity, and impact on patient safety) guides prioritization and resource allocation.

Regulatory and Compliance Considerations

Regulatory bodies (like the FDA) expect life sciences organizations to manage cybersecurity and vulnerability risks. Recent FDA guidance emphasizes the importance of software updates and vulnerability management. ServiceNow Vulnerability Response records documenting assessments, remediations, and risk acceptances provide evidence of responsible vulnerability management. Conversely, a lack of evidence of vulnerability management is a compliance red flag.

Organizations should also consider supply chain risk. If a third-party vendor provides manufacturing software or medical devices with known vulnerabilities, that is a supply chain risk. ServiceNow can track vendor vulnerabilities and coordinate communication with vendors on patches and remediation timelines.

Compensating Controls

When patches are not available or cannot be applied immediately, organizations implement compensating controls. Examples: network segmentation (isolating a vulnerable system from the internet and untrusted networks), access restrictions (limiting who can access the system), monitoring and intrusion detection (alerting if the system is compromised), and air-gapping (running the system on a network with no internet connectivity).

ServiceNow Vulnerability Response should document compensating controls: what control is in place, when it was implemented, and how it mitigates the vulnerability risk. This documentation is essential for audit and regulatory review, demonstrating that the organization is managing the risk even though the vulnerability is not patched.

Example: Critical Vulnerability in Manufacturing Software

A critical vulnerability is discovered in a manufacturing data system used in production. The system is validated for GMP use. A patch is available from the vendor, but applying the patch requires revalidation of the system. The vulnerability can be exploited remotely, but the system is behind a firewall and accessible only from internal networks. The organization assesses: the risk is moderate (internally accessible but critical vulnerability). Revalidation would take four weeks. In the meantime, the organization implements compensating controls: restricting access to a smaller set of users, enabling detailed audit logging, and deploying intrusion detection on the network segment. The organization schedules revalidation for four weeks out and applies the patch once revalidation testing is complete.

Choosing a remediation path before opening a patch ticket

When a critical vulnerability is confirmed on a validated system, the security team’s instinct is to patch quickly. In a regulated environment the patch is only one of several remediation paths, and choosing the wrong one can create a larger problem than the vulnerability. A patch applied without a change assessment can invalidate a validated state. A compensating control applied without a documented decision looks, to an auditor, like an unmanaged risk. This section is for vulnerability managers and security engineers who work alongside validation and biomedical teams, and who need a decision sequence that all three functions can follow.

The decision has five outcomes, and each one should be recorded as a deliberate choice: patch now, patch after revalidation, apply compensating controls until a fix is validated, retire or replace the item, or accept the risk for a stated period. None of these is the default. The default is whatever the item record says, and many item records say nothing until someone fills them in.

A decision table for validated and clinical systems

The table makes one point plainly. A risk acceptance on a validated system must have an expiry date. An accepted risk with no end date is a permanent exception that nobody is watching.

Recording a risk acceptance an inspector can follow

1. State the vulnerability, the affected validated configuration item and the process it supports, in terms a quality reviewer can read without the technical detail.
2. Describe the compensating controls in place and how each one reduces exposure, such as restricting access to named roles or isolating the network segment.
3. Name the approver. For validated systems this should include quality, not only the security lead and the system owner.
4. Set an expiry date and the event that would trigger an earlier review, such as a vendor fix being released or the system being changed for another reason.
5. Attach the evidence that the controls are operating, such as an access list export or a monitoring configuration screenshot, and record when it was taken.
6. Schedule the re-decision and do not close the item until the re-decision is recorded.

Where scanner-driven workflows go wrong in this sector

A vulnerability scanner that reruns after a patch will often show the finding as resolved, and the item may close automatically. In a validated environment, that closure can be premature. The scanner confirms the software version changed. It does not confirm that the validated configuration matches its approval, or that the compensating control is in place. Build the closure rule so that an automated resolution moves the item to a verification step owned by a person, rather than closing it outright.

A second pattern is ownership confusion between IT, operational technology and biomedical engineering. A laboratory analyzer may appear in the scan under IT but be maintained by the instrument vendor and the biomedical team. Agree the owner for each device class before the first scan, and record it on the configuration item so the item routes correctly.

Measures that describe the health of the process

Look at the count of validated-system items with a current decision recorded, the number of risk acceptances approaching their expiry, the share of closures supported by verification evidence rather than scanner output, and the time between vendor fix release and a documented decision. These measures describe whether decisions are being made, which is what matters to a reviewer. Speed of closure on its own is not a useful measure in this setting.

Who should sign a risk acceptance for a validated system?

The approver should hold authority over both the security exposure and the validated state. In many organizations that means the system owner and quality together, with security as the reviewing function. A signature from security alone does not address the regulatory dimension.

What if the vendor has not released a fix for a device we depend on?

Record the vendor correspondence, the compensating controls in place and the decision date. Set a review that is triggered by a vendor statement rather than only by the calendar, and consider whether the device should be replaced if the exposure cannot be contained.

Can a scanner result alone close a vulnerability on a validated system?

Not without a verification step owned by a person. The scanner shows the software state at the time of the scan. The verification step confirms that the change was approved, that validation was preserved, and that any compensating control is no longer needed or is still working.

How often should compensating controls be checked?

Set the frequency from the risk and the review date recorded in the acceptance, not from a standard interval. A control on an internet-exposed system warrants more frequent checks than one on an isolated network, and the frequency should be written in the acceptance so it can be audited.

To work through the decision paths with someone who has built them, speak to a ServiceNow specialist. The wider model is described in vulnerability exposure response, and the ownership workflow article covers how findings are assigned with asset and service context.